Miglustat Therapy for SCARB2-Associated Action Myoclonus-Renal Failure Syndrome.

Neurology. Genetics
Imran H QuraishiLawrence J Hirsch

Abstract

We evaluated whether substrate reduction therapy with miglustat could alter the course of action myoclonus-renal failure syndrome (AMRF), a rare, progressive myoclonic epilepsy with early mortality caused by scavenger receptor class B member 2 (SCARB2) gene mutations. We identified an AMRF patient with a biallelic combination of SCARB2 mutations determined by whole exome sequencing. SCARB2 encodes a protein that traffics β-glucocerebrosidase to the lysosomal membrane. Mutations lead to a complex pattern of glucosylceramide accumulation and neurologic symptoms including progressive action myoclonus, seizures, and ataxia. We then evaluated the effect of inhibiting glucosylceramide synthesis, as is used in Gaucher disease. The patient was treated for 3 years with miglustat after several years of steady worsening. Progression of myoclonus halted, dysphagia resolved, some skills were reacquired, and seizures remained well controlled. The response suggests that neurologic symptoms of SCARB2-associated AMRF could be ameliorated, at least partly, by targeting glycosphingolipid metabolism with available medications.

References

Sep 15, 2004·Brain : a Journal of Neurology·AmanPreet BadhwarEva Andermann
Apr 22, 2008·Human Molecular Genetics·Andrea BalreiraMaria Clara Sá Miranda
Dec 11, 2008·Annals of Neurology·Raphael SchiffmannAshok Vellodi
Oct 23, 2009·Annals of Neurology·L M DibbensS F Berkovic
Jul 26, 2011·Seizure : the Journal of the British Epilepsy Association·João ChavesJosé L Lima
Oct 5, 2012·Annals of Neurology·Matthew E GeggAnthony H V Schapira
Sep 2, 2016·Epileptic Disorders : International Epilepsy Journal with Videotape·Leanne DibbensGuido Rubboli
Aug 30, 2019·Molecular Neurodegeneration·Jenny DoEllen Sidransky
Nov 16, 2019·Movement Disorders : Official Journal of the Movement Disorder Society·Giovanni BellomoLucilla Parnetti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.